Sam L. Teichman

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison et al. · The Lancet · 2012 · 896 citations

Heart Failure, Cardiac Anaesthesia, Cardiogenic Shock +10

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

Marco Metra, Gad Cotter, Beth A. Davison et al. · Journal of the American College of Cardiology · 2012 · 423 citations · Full text

Heart Failure, Stress, Medicine +10

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

John R. Teerlink, Marco Metra, G. Michael Felker et al. · The Lancet · 2009 · 419 citations

Heart Failure, Cardiac Anaesthesia, Cardiogenic Shock +8

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

Stanley D. Bleich, Timothy C. Nichols, Richard R. Schumacher et al. · The American Journal of Cardiology · 1990 · 267 citations

Thrombosis, Coronary Arterial Patency, Cardiovascular Disease +12

SGS742: the first GABAB receptor antagonist in clinical trials

Wolfgang Froestl, Michela Gallagher, Helen Jenkins et al. · Biochemical Pharmacology · 2004 · 187 citations

G Protein-coupled Receptor, Pharmacology, Clinical Trials +3